___________________________________________________________________________________________________________________________________________
Outstanding Share Data October 31 ,2016,the Company had
41,955,126 common shares issued and outstanding
July 31,2016 the Company had
41,427,352 common shares issued and outstanding
April 27,2016 the Company had
40,987,145 common shares issued and outstanding
February 29,2016 the Company had
40,004,037 common shares issued and outstanding
November 1,2015 the Company had
39,875,405 common shares issued and outstanding
August 1,2015 the Company had
39,703,998 common shares issued and outstanding
May 1,2015 the Company had
35,816,364 common shares issued and outstanding
February 28,2015 the Company had
29,091,773 common shares issued and outstanding
November 10,2014 the Company had
22,939,553 common shares issued and outstanding
____________________________________________________________________________________________________________________________________________
MAJOR HOLDERS
68% of the outstanding owned by these longs
Outstanding 42mil minus Major ownership of 28.5mil = 13.5mil free trading float
28.5mil Major Holders in this,15mil Institutions,7.5mil Direct Holders,6mil Mutual Funds= 68% of 42mil os http://www.barrons.com/quote/stock/us/xnas/anth?mod=DNH_S ________________________________________________________________ Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,
including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into
PHASE 3
Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),
now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment
of lupus.
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous
countries by year's end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.
The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as
it currently has more desirable features than that of Benlysta.
Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a
series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to
specific patient populations and has not been studied in combination with other biologics.
These attributes of blisibimod including a different mechanism of action, will set it apart from
Benlysta, Global Data concludes.